Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.
Alexis OgdieJoseph F MerolaPhilip J MeaseChristopher T RitchlinJose U ScherKimberly Parnell LaffertyDaphne ChanSoumya D ChakravartyWayne LangholffYanli WangOlivia ChoiYevgeniy KrolAlice B GottliebPublished in: BMC rheumatology (2024)
This trial was registered at ClinicalTrials.gov, NCT04936308, on 23 June 2021.